ZA201007373B - Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation - Google Patents

Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation

Info

Publication number
ZA201007373B
ZA201007373B ZA2010/07373A ZA201007373A ZA201007373B ZA 201007373 B ZA201007373 B ZA 201007373B ZA 2010/07373 A ZA2010/07373 A ZA 2010/07373A ZA 201007373 A ZA201007373 A ZA 201007373A ZA 201007373 B ZA201007373 B ZA 201007373B
Authority
ZA
South Africa
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Application number
ZA2010/07373A
Other languages
English (en)
Inventor
Richard Boyd White
Ian Cottingham
Daniel Plaksin
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201007373(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of ZA201007373B publication Critical patent/ZA201007373B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2010/07373A 2008-04-16 2010-10-14 Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation ZA201007373B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
ZA201007373B true ZA201007373B (en) 2011-06-29

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07373A ZA201007373B (en) 2008-04-16 2010-10-14 Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation

Country Status (29)

Country Link
US (6) US8951967B2 (https=)
EP (7) EP2722339A1 (https=)
JP (7) JP2011519359A (https=)
KR (5) KR20170110741A (https=)
CN (3) CN105906703A (https=)
AR (1) AR071479A1 (https=)
AU (5) AU2009237479B2 (https=)
BR (1) BRPI0910461B8 (https=)
CA (1) CA2725257A1 (https=)
CY (1) CY1115413T1 (https=)
DK (6) DK2268666T3 (https=)
ES (5) ES2629392T3 (https=)
FI (4) FI4015527T3 (https=)
FR (3) FR17C1020I2 (https=)
HR (5) HRP20140535T1 (https=)
HU (9) HUE068565T2 (https=)
IL (2) IL208538A (https=)
LT (8) LT3045471T (https=)
MX (3) MX348622B (https=)
NO (4) NO2017025I1 (https=)
NZ (1) NZ588381A (https=)
PL (6) PL3144318T3 (https=)
PT (6) PT3144318T (https=)
RU (3) RU2537268C2 (https=)
SA (1) SA109300228B1 (https=)
SI (6) SI2268666T1 (https=)
TW (1) TWI488640B (https=)
WO (1) WO2009127826A1 (https=)
ZA (1) ZA201007373B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
EP3662925B1 (en) 2015-04-17 2021-04-07 Ferring B.V. Composition comprising fsh for treatment of infertility
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
US11744879B2 (en) 2017-09-01 2023-09-05 Ferring B.V. Recombinant FSH composition for controlled ovarian stimulation
RS66871B1 (sr) 2018-04-30 2025-06-30 Ferring Bv Kompozicija za kontrolisanu stimulaciju jajnika
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
AU2023302100A1 (en) 2022-07-08 2025-01-02 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CA2278178C (en) 1997-01-16 2012-09-25 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
PT1176976E (pt) 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
ES2261740T3 (es) * 2001-10-22 2006-11-16 Applied Research Systems Ars Holding N.V. Composiciones de fsh con alto grado de sialilacion y su uso para la preparacion de medicamentos.
CA2756610C (en) 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
DE602005022675D1 (de) 2004-02-04 2010-09-16 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Also Published As

Publication number Publication date
BRPI0910461A2 (pt) 2018-03-27
HUS1700025I1 (hu) 2017-06-28
JP2018021037A (ja) 2018-02-08
ES2989729T3 (es) 2024-11-27
EP4015527B1 (en) 2025-01-22
DK3144318T3 (da) 2020-12-07
AR071479A1 (es) 2010-06-23
EP3045471A1 (en) 2016-07-20
NZ588381A (en) 2012-05-25
RU2682270C2 (ru) 2019-03-18
RU2010141908A (ru) 2012-05-27
WO2009127826A1 (en) 2009-10-22
HUE068565T2 (hu) 2025-01-28
SA109300228B1 (ar) 2014-04-08
NO2025032I1 (no) 2025-07-14
EP2268666B1 (en) 2014-03-12
LTPA2017018I1 (lt) 2017-06-26
PL3098234T3 (pl) 2025-01-07
PT3045471T (pt) 2017-06-14
CY1115413T1 (el) 2017-01-04
FR17C1020I1 (https=) 2020-04-10
HUE033830T2 (en) 2018-01-29
CN102066414A (zh) 2011-05-18
HUE030652T4 (en) 2017-09-28
EP3144318B1 (en) 2020-09-23
HUS2500029I1 (hu) 2025-07-28
JP6762916B2 (ja) 2020-09-30
DK3045471T3 (en) 2017-06-26
ES2629392T3 (es) 2017-08-09
JP6486310B2 (ja) 2019-03-20
FIC20250003I1 (fi) 2025-01-15
BRPI0910461B8 (pt) 2021-05-25
AU2014203277A1 (en) 2014-07-24
NO2025006I1 (no) 2025-01-16
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
ES2468318T3 (es) 2014-06-16
JP2015120696A (ja) 2015-07-02
MX355457B (es) 2018-04-19
US20160347811A1 (en) 2016-12-01
KR20160056960A (ko) 2016-05-20
BRPI0910461A8 (pt) 2018-10-16
US9771407B2 (en) 2017-09-26
AU2017204258A1 (en) 2017-07-20
JP2022031652A (ja) 2022-02-22
DK2268666T3 (da) 2014-05-12
EP3098234B1 (en) 2024-07-31
LT4015527T (lt) 2025-04-10
IL208538A0 (en) 2010-12-30
IL230571A (en) 2015-11-30
SI3144318T1 (sl) 2020-12-31
JP7316905B2 (ja) 2023-07-28
US11952407B2 (en) 2024-04-09
EP2722339A1 (en) 2014-04-23
RU2745557C3 (ru) 2021-12-10
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HRP20170958T1 (hr) 2017-09-22
HUS1700036I1 (hu) 2017-10-30
AU2009237479A1 (en) 2009-10-22
RU2014141994A3 (https=) 2018-05-28
SI4015527T1 (sl) 2025-05-30
JP2017060476A (ja) 2017-03-30
FIC20250025I1 (fi) 2025-07-11
US12516094B2 (en) 2026-01-06
EP2268666A1 (en) 2011-01-05
US20110105398A1 (en) 2011-05-05
LT2808340T (lt) 2016-11-10
FR25C1025I1 (fr) 2025-09-19
HUE030652T2 (en) 2017-05-29
AU2014203277B2 (en) 2017-04-06
LT3045471T (lt) 2017-07-10
HRP20161520T1 (hr) 2016-12-30
US20240327487A1 (en) 2024-10-03
RU2745557C1 (ru) 2021-03-29
PT3144318T (pt) 2020-11-04
EP3144318A1 (en) 2017-03-22
AU2017225020B2 (en) 2019-11-14
HUE071059T2 (hu) 2025-07-28
US20210332099A1 (en) 2021-10-28
PL2268666T3 (pl) 2014-08-29
US20180079794A1 (en) 2018-03-22
FR25C1003I1 (fr) 2025-02-28
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
EP2808340A1 (en) 2014-12-03
KR20110005863A (ko) 2011-01-19
SI3098234T1 (sl) 2024-10-30
PT2268666E (pt) 2014-06-25
LT3098234T (lt) 2024-09-10
EP3098234A1 (en) 2016-11-30
PL3144318T3 (pl) 2021-02-08
CN105906703A (zh) 2016-08-31
KR20170110741A (ko) 2017-10-11
EP2808340B1 (en) 2016-08-17
CN105906702A (zh) 2016-08-31
JP2020040956A (ja) 2020-03-19
DK2808340T3 (en) 2016-12-05
EP3045471B1 (en) 2017-03-29
AU2017204259A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
HUS1700024I1 (hu) 2017-06-28
SI3045471T1 (sl) 2017-07-31
MX348622B (es) 2017-06-22
SI2268666T1 (sl) 2014-07-31
HK1146284A1 (en) 2011-05-20
KR20180095140A (ko) 2018-08-24
AU2017225020A1 (en) 2017-09-28
LTPA2017029I1 (lt) 2017-10-10
DK3098234T3 (da) 2024-10-21
US20150065695A1 (en) 2015-03-05
PL3045471T3 (pl) 2017-10-31
SI2808340T1 (sl) 2016-12-30
BRPI0910461B1 (pt) 2021-02-23
RU2537268C2 (ru) 2014-12-27
EP4015527A1 (en) 2022-06-22
FI3098234T3 (fi) 2024-10-31
LTPA2025505I1 (https=) 2025-02-10
KR101622944B1 (ko) 2016-05-23
FI4015527T3 (fi) 2025-04-29
US10995128B2 (en) 2021-05-04
TWI488640B (zh) 2015-06-21
HRP20250313T1 (hr) 2025-05-09
PT2808340T (pt) 2016-11-21
IL208538A (en) 2014-03-31
KR102108377B1 (ko) 2020-05-08
US8951967B2 (en) 2015-02-10
NO2017025I1 (no) 2017-06-06
LTPA2025525I1 (https=) 2025-07-25
PL2808340T3 (pl) 2017-02-28
AU2014203277C1 (en) 2017-07-27
HK1199039A1 (en) 2015-06-19
AU2017204258B2 (en) 2017-08-17
ES3023526T3 (en) 2025-06-02
HUS2500008I1 (hu) 2025-02-28
CA2725257A1 (en) 2009-10-22
FR17C1020I2 (fr) 2020-04-10
TW200948378A (en) 2009-12-01
PT3098234T (pt) 2024-10-21
AU2017204259B2 (en) 2017-08-17
KR20190092608A (ko) 2019-08-07
HRP20241187T1 (hr) 2024-12-06
NO2017050I1 (no) 2017-09-28
JP2011519359A (ja) 2011-07-07
PT4015527T (pt) 2025-04-10
DK4015527T3 (da) 2025-04-14
AU2009237479B2 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
HUS2500029I1 (hu) Alfa 2,3- és alfa 2,6-szalizációt tartalmazó rekombináns FSH
SI3581631T1 (sl) Sestavki, ki obsegajo 2,3,3,3-tetrafluoropropen
IL211762A (en) Pegillacie opioids, preparations containing them and their uses
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
AP2010005388A0 (en) Pupicidal and larvicidal composition.
IL207174A0 (en) Peptides, compositions, and uses thereof
LT3144318T (lt) Rekombinantinis fsh, įskaitant alfa-2,3- ir alfa-2,6-sialilinimą
GB0808401D0 (en) Fsh
GB0813815D0 (en) Corcost Pre 1001,10
GB0809709D0 (en) Dunhill car,2093
GB0705503D0 (en) The buffer
GB0808811D0 (en) Algabe 2.1